Chengwei Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chengwei Wang has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
Guidong Zhu
Department of Neurosurgery, The Second Qilu Hospital of Shandong University, Jinan, People's Republic of China
6 shared publicationsXuan Ding
Department of Neurosurgery, The Second Hospital of Shandong University, Jinan, People’s Republic of China
4 shared publicationsBaowang Miao
Department of Neurosurgery, The Second Qilu Hospital of Shandong University, Jinan, People's Republic of China
3 shared publicationsChao Han
Department of Neurosurgery, The Second Hospital of Shandong University, Jinan, People’s Republic of China
3 shared publications- Dongqi Tang
Center for Gene and Immunotherapy, Multidisciplinary Innovation Center for Nephrology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China
3 shared publications Ping Zhang
Department of Neurosurgery, Qilu Hospital, Cheeloo College of Medicine and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan, P. R. China
3 shared publications
Latest Publications
- 22 June 2026
- Published by Elsevier in Environmental Pollution
- Vol. 406, 128624
Multi-omics analyses reveal BPA accelerates glioma progression via cell cycle dysregulation
- 22 June 2026
- Published by Elsevier in Environmental Pollution
- Vol. 406, 128624
Multi-omics analyses reveal BPA accelerates glioma progression via cell cycle dysregulation
- Open Access
- 18 April 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Augmenting the catalytic activity of ADzymes: strategic engineering from atomic structure design to macro-environmental interaction for enhanced biomedical efficacy
Nanozymes with atomically dispersed metal sites (ADzymes), characterized by well-defined active centers, high catalytic efficiency, and tunable catalytic properties, have expanded the horizons for developing bio-inspired solutions to address critical challenges in healthcare domains. Herein, this article systematically reviews the synthesis and characterization methods, and classification system of ADzymes, and summarizes the strategies to enhance their catalytic activity ranging from micro- to macro-scales. Key strategies discussed include the biomimetic design of metal active centers, modulation of coordination environments, support interface engineering, and external-field-responsive dynamic activation. Furthermore, the potential applications of ADzymes in ROS-mediated biomedical therapies are highlighted. Based on the systematic deconstruction of the structure-activity relationship, this review provides a theoretical foundation for the rational design of high-performance artificial enzymes. Finally, the current bottlenecks and future perspectives regarding the regulation of ADzymes for clinical translation are discussed, providing insights into their evolution from empirical screening to intelligent design.
- 18 April 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessAugmenting the catalytic activity of ADzymes: strategic engineering from atomic structure design to macro-environmental interaction for enhanced biomedical efficacy
Nanozymes with atomically dispersed metal sites (ADzymes), characterized by well-defined active centers, high catalytic efficiency, and tunable catalytic properties, have expanded the horizons for developing bio-inspired solutions to address critical challenges in healthcare domains. Herein, this article systematically reviews the synthesis and characterization methods, and classification system of ADzymes, and summarizes the strategies to enhance their catalytic activity ranging from micro- to macro-scales. Key strategies discussed include the biomimetic design of metal active centers, modulation of coordination environments, support interface engineering, and external-field-responsive dynamic activation. Furthermore, the potential applications of ADzymes in ROS-mediated biomedical therapies are highlighted. Based on the systematic deconstruction of the structure-activity relationship, this review provides a theoretical foundation for the rational design of high-performance artificial enzymes. Finally, the current bottlenecks and future perspectives regarding the regulation of ADzymes for clinical translation are discussed, providing insights into their evolution from empirical screening to intelligent design.
- Open Access
- 1 February 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-16
LincRNA-p21: A Double-Edged Sword in Ethanol-Induced Liver Damage and Its Nanoparticle Solution
Background: Alcohol-related liver disease (ALD) is the leading cause of liver disease-related deaths globally, necessitating new treatments. This study investigates the role of long intergenic noncoding RNA (lincRNA)-p21 in ALD and explores therapeutic strategies for liver injury. We identified lncRNAs linked to ethanol-induced liver injury using the Gene Expression Omnibus (GEO) database. Experiments were conducted to assess the function of lincRNA-p21 in ALD both in vivo and in vitro. Autophagy was analyzed through electron microscopy, autophagic flow, and protein expression. Bioinformatics explored underlying mechanisms, focusing on m6A modification of lincRNA-p21 by ALKBH5 using RNA Immunoprecipitation (RIP) and meRIP-PCR. Ferroptosis was induced with erastin, and its levels were measured by cell ROS and viability. A nanoplatform-based system was developed to co-deliver a plasmid encoding lincRNA-p21 and a ferroptosis inhibitor. We developed a nanoplatform-based co-delivery system to deliver a plasmid encoding lincRNA-p21 and the ferroptosis inhibitor ferrostatin-1 (ferr-1/lincRNA-p21@NP) to the liver. LincRNA-p21 protected liver cells against ethanol-induced injury by promoting autophagy. ALKBH5 mediated the m6A demethylation and lincRNA-p21 upregulation. However, we revealed a dual-edged sword function for lincRNA-p21 in ethanol-induced liver injury in mice. LincRNA-p21 reduced acute ethanol-induced cell injury by enhancing autophagy but exacerbated chronic ethanol-induced liver cell injury by increasing ferroptosis. In vivo and in vitro analyses showed favorable therapeutic effects of ferr-1/lincRNA-p21@NPs on ALD. These results show that lincRNA-p21 affects autophagy and ferroptosis, and the ferr-1/lincRNA-p21@NP nanosystem can provide protection against ALD.
- 1 February 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1-16
Open AccessLincRNA-p21: A Double-Edged Sword in Ethanol-Induced Liver Damage and Its Nanoparticle Solution
Background: Alcohol-related liver disease (ALD) is the leading cause of liver disease-related deaths globally, necessitating new treatments. This study investigates the role of long intergenic noncoding RNA (lincRNA)-p21 in ALD and explores therapeutic strategies for liver injury. We identified lncRNAs linked to ethanol-induced liver injury using the Gene Expression Omnibus (GEO) database. Experiments were conducted to assess the function of lincRNA-p21 in ALD both in vivo and in vitro. Autophagy was analyzed through electron microscopy, autophagic flow, and protein expression. Bioinformatics explored underlying mechanisms, focusing on m6A modification of lincRNA-p21 by ALKBH5 using RNA Immunoprecipitation (RIP) and meRIP-PCR. Ferroptosis was induced with erastin, and its levels were measured by cell ROS and viability. A nanoplatform-based system was developed to co-deliver a plasmid encoding lincRNA-p21 and a ferroptosis inhibitor. We developed a nanoplatform-based co-delivery system to deliver a plasmid encoding lincRNA-p21 and the ferroptosis inhibitor ferrostatin-1 (ferr-1/lincRNA-p21@NP) to the liver. LincRNA-p21 protected liver cells against ethanol-induced injury by promoting autophagy. ALKBH5 mediated the m6A demethylation and lincRNA-p21 upregulation. However, we revealed a dual-edged sword function for lincRNA-p21 in ethanol-induced liver injury in mice. LincRNA-p21 reduced acute ethanol-induced cell injury by enhancing autophagy but exacerbated chronic ethanol-induced liver cell injury by increasing ferroptosis. In vivo and in vitro analyses showed favorable therapeutic effects of ferr-1/lincRNA-p21@NPs on ALD. These results show that lincRNA-p21 affects autophagy and ferroptosis, and the ferr-1/lincRNA-p21@NP nanosystem can provide protection against ALD.
- Open Access
- 31 January 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Targeting hypoxic exosomal IGFBP2 overcomes CD47-mediated immune evasion in glioblastoma
Glioblastoma (GBM) acquires malignant traits through complex molecular adaptations that sustain immune evasion, often characterized by hypoxia and overexpression of the phagocytosis checkpoint CD47. However, the role of hypoxic drivers coordinating CD47-dependent immune evasion remains poorly defined. Here, we integrated single cell RNA sequencing and proteomic analysis to identify that insulin-like growth factor binding protein 2 (IGFBP2) was co-expressed with CD47 in hypoxic mesenchymal-like GBM subpopulations, synergistically promoting tumor progression and immune evasion. Mechanically, hypoxia induced IGFBP2 expression via HIF-2α-mediated transcriptional activation and further increased IGFBP2-positive exosome secretion through HIF-1α-dependent RAB3A upregulation. Moreover, IGFBP2 was predominantly localized on the exosome surface via integrin α5β1 and activated integrin/FAK/STAT3 signaling to enhance CD47 expression and inhibit macrophage phagocytosis. Clinically, serum exosomal IGFBP2 levels correlated with tumor grade and could serve as a diagnostic biomarker. Importantly, combinatorial blockade of IGFBP2 and CD47 synergistically suppressed tumor growth and prolonged survival in orthotopic GBM models. Together, our findings uncovered the hypoxia-exosomal IGFBP2-CD47 axis in GBM immune evasion and provided a compelling rationale for combination therapy to improve immunotherapy efficacy in GBM.
- 31 January 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessTargeting hypoxic exosomal IGFBP2 overcomes CD47-mediated immune evasion in glioblastoma
Glioblastoma (GBM) acquires malignant traits through complex molecular adaptations that sustain immune evasion, often characterized by hypoxia and overexpression of the phagocytosis checkpoint CD47. However, the role of hypoxic drivers coordinating CD47-dependent immune evasion remains poorly defined. Here, we integrated single cell RNA sequencing and proteomic analysis to identify that insulin-like growth factor binding protein 2 (IGFBP2) was co-expressed with CD47 in hypoxic mesenchymal-like GBM subpopulations, synergistically promoting tumor progression and immune evasion. Mechanically, hypoxia induced IGFBP2 expression via HIF-2α-mediated transcriptional activation and further increased IGFBP2-positive exosome secretion through HIF-1α-dependent RAB3A upregulation. Moreover, IGFBP2 was predominantly localized on the exosome surface via integrin α5β1 and activated integrin/FAK/STAT3 signaling to enhance CD47 expression and inhibit macrophage phagocytosis. Clinically, serum exosomal IGFBP2 levels correlated with tumor grade and could serve as a diagnostic biomarker. Importantly, combinatorial blockade of IGFBP2 and CD47 synergistically suppressed tumor growth and prolonged survival in orthotopic GBM models. Together, our findings uncovered the hypoxia-exosomal IGFBP2-CD47 axis in GBM immune evasion and provided a compelling rationale for combination therapy to improve immunotherapy efficacy in GBM.
- Open Access
- 18 December 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1)
Microgravity-cultured glioblastoma organoids integrated with microfluidic chip for CAR-γδ T evaluation
Tumor organoids mimicking the tumor microenvironment (TME) are key tools for tumor immunity research and personalized cancer therapy development. We integrated microgravity culture with microfluidic chip technology (Micro-GRA& FLU) to establish a platform for evaluating chimeric antigen receptor (CAR)-γδ T cell efficacy under physiological-like conditions. Patient-derived glioblastoma (GBM) cells were microgravity-cultured into glioblastoma organoids (GBOs). Pathological analysis validated GBO similarity to matched GBM in immune cell phenotypes. Microfluidic chips assessed CAR-γδ T cell cytotoxicity against GBOs. The low-cost, easy-to-operate microgravity system generated viable, uniform GBOs that retained GBM TME features. CAR-γδ T cells showed strong cytotoxicity against GBOs in microfluidic chips; individualized combination therapy enhanced their antitumor activity vs. monotherapy. This study establishes a scalable, physiologically relevant Micro-GRA& FLU platform for evaluating CAR-γδ T cell therapies in GBM organoids.
- 18 December 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1)
Open AccessMicrogravity-cultured glioblastoma organoids integrated with microfluidic chip for CAR-γδ T evaluation
Tumor organoids mimicking the tumor microenvironment (TME) are key tools for tumor immunity research and personalized cancer therapy development. We integrated microgravity culture with microfluidic chip technology (Micro-GRA& FLU) to establish a platform for evaluating chimeric antigen receptor (CAR)-γδ T cell efficacy under physiological-like conditions. Patient-derived glioblastoma (GBM) cells were microgravity-cultured into glioblastoma organoids (GBOs). Pathological analysis validated GBO similarity to matched GBM in immune cell phenotypes. Microfluidic chips assessed CAR-γδ T cell cytotoxicity against GBOs. The low-cost, easy-to-operate microgravity system generated viable, uniform GBOs that retained GBM TME features. CAR-γδ T cells showed strong cytotoxicity against GBOs in microfluidic chips; individualized combination therapy enhanced their antitumor activity vs. monotherapy. This study establishes a scalable, physiologically relevant Micro-GRA& FLU platform for evaluating CAR-γδ T cell therapies in GBM organoids.
- Open Access
- 9 December 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1676103
Sialylation-related gene signature predict prognosis and immunotherapy efficacy in low- and high-grade glioma: a PCA-based stratification study
Background: Sialylation is a crucial glycosylation modification of eukaryotic cell surface proteins. Tumor cell growth, immune evasion, and drug resistance are driven by excessive sialylation. However, the expression levels of genes associated with sialylation, prognostic value, and impact on the response to immunotherapy in brain tumors remain unclear. This study hypothesized that sialylation-related genes could serve as grouping genes to identify 20 significant genes for predicting the survival outcomes of patients with brain tumors and their responsiveness to immune checkpoint inhibitors. Methods: Using 83 genes related to sialylation, we classified the cohort into two distinct groups with marked differences in survival outcomes and immune cell infiltration. After identifying the differential genes, we subsequently performed unsupervised clustering, yielding two groups with high concordance. Principal component analysis (PCA) was used for dimensionality reduction in the two groups, with the PC1 and PC2 components defined as the PCA score. Results: A positive correlation was observed between the PCA score and immune cell infiltration, immune checkpoint expression, as well as chemokine expression, suggesting enhanced immunotherapy efficacy. We also validated the expression levels of KCNIP3 in patient tissues and found that this gene was overexpressed in U87 and LN229 cells, with low endogenous expression. These results demonstrate that KCNIP3 inhibits tumor cell proliferation, migration, and invasion. Moreover, intracranial xenograft results in mice were consistent with the in vitro findings. Conclusion: We developed a robust model to predict patient prognosis in low-grade gliomas and glioblastomas, emphasizing the prognostic significance of differentially expressed genes associated with sialylation.
- 9 December 2025
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1676103
Open AccessSialylation-related gene signature predict prognosis and immunotherapy efficacy in low- and high-grade glioma: a PCA-based stratification study
Background: Sialylation is a crucial glycosylation modification of eukaryotic cell surface proteins. Tumor cell growth, immune evasion, and drug resistance are driven by excessive sialylation. However, the expression levels of genes associated with sialylation, prognostic value, and impact on the response to immunotherapy in brain tumors remain unclear. This study hypothesized that sialylation-related genes could serve as grouping genes to identify 20 significant genes for predicting the survival outcomes of patients with brain tumors and their responsiveness to immune checkpoint inhibitors. Methods: Using 83 genes related to sialylation, we classified the cohort into two distinct groups with marked differences in survival outcomes and immune cell infiltration. After identifying the differential genes, we subsequently performed unsupervised clustering, yielding two groups with high concordance. Principal component analysis (PCA) was used for dimensionality reduction in the two groups, with the PC1 and PC2 components defined as the PCA score. Results: A positive correlation was observed between the PCA score and immune cell infiltration, immune checkpoint expression, as well as chemokine expression, suggesting enhanced immunotherapy efficacy. We also validated the expression levels of KCNIP3 in patient tissues and found that this gene was overexpressed in U87 and LN229 cells, with low endogenous expression. These results demonstrate that KCNIP3 inhibits tumor cell proliferation, migration, and invasion. Moreover, intracranial xenograft results in mice were consistent with the in vitro findings. Conclusion: We developed a robust model to predict patient prognosis in low-grade gliomas and glioblastomas, emphasizing the prognostic significance of differentially expressed genes associated with sialylation.
- Open Access
- 31 October 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (50) , 42432-42442
Magnetically guided Bi 2 S 3 @C/Fe 3 O 4 nanoparticles for enhanced photothermal-radiation synergy in glioblastoma treatment
Preparation of Bi 2 S 3 @C/Fe 3 O 4 and its application in combined PTT-RT for the synergistic treatment of glioma.
- 31 October 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (50) , 42432-42442
Open AccessMagnetically guided Bi 2 S 3 @C/Fe 3 O 4 nanoparticles for enhanced photothermal-radiation synergy in glioblastoma treatment
Preparation of Bi 2 S 3 @C/Fe 3 O 4 and its application in combined PTT-RT for the synergistic treatment of glioma.
- Open Access
- 20 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (19) , e2501772
Rational Design and Organoid‐Based Evaluation of a Cocktail CAR‐γδ T Cell Therapy for Heterogeneous Glioblastoma
Various challenges, including tumor heterogeneity and inadequate T cell infiltration, impede the progress of chimeric antigen receptor T cell (CAR‐T) therapy for glioblastoma (GBM). To address these obstacles, a multiple step strategy is designed. Initially, literature review and bioinformatics analysis to screen a set of antigens that are heterogeneously expressed in GBM, which are designated as the target‐bank, are leveraged. Then, according to the multiplex immunohistochemistry results of each patient's tumor sample, a personalized panel of antigens based on the principle that most cancer cells in tumor tissues can be covered from the target‐bank is selected. To target these antigens, Vδ1 T cells are chosen as CAR vehicles because of its high tissue infiltration and off‐the‐shelf properties, and an optimized protocol for engineering CAR‐Vδ1 T cells with high purity and cytotoxicity, low exhaustion, and cytokine release is developed. Next, the specific panel of cocktail CAR‐Vδ1 T cells in the GBM organoids that are directly derived from the same patient's tumor is tested. The term “prof” cocktail therapy is coined to describe the approach using precise and rational combination of tumor antigens, organoid‐based evaluation, and fitness of Vδ1 T cells. It may accelerate development of effective CAR‐T drugs for heterogeneous solid tumors.
- 20 March 2025
- Published by Wiley in Advanced Science
- Vol. 12 (19) , e2501772
Open AccessRational Design and Organoid‐Based Evaluation of a Cocktail CAR‐γδ T Cell Therapy for Heterogeneous Glioblastoma
Various challenges, including tumor heterogeneity and inadequate T cell infiltration, impede the progress of chimeric antigen receptor T cell (CAR‐T) therapy for glioblastoma (GBM). To address these obstacles, a multiple step strategy is designed. Initially, literature review and bioinformatics analysis to screen a set of antigens that are heterogeneously expressed in GBM, which are designated as the target‐bank, are leveraged. Then, according to the multiplex immunohistochemistry results of each patient's tumor sample, a personalized panel of antigens based on the principle that most cancer cells in tumor tissues can be covered from the target‐bank is selected. To target these antigens, Vδ1 T cells are chosen as CAR vehicles because of its high tissue infiltration and off‐the‐shelf properties, and an optimized protocol for engineering CAR‐Vδ1 T cells with high purity and cytotoxicity, low exhaustion, and cytokine release is developed. Next, the specific panel of cocktail CAR‐Vδ1 T cells in the GBM organoids that are directly derived from the same patient's tumor is tested. The term “prof” cocktail therapy is coined to describe the approach using precise and rational combination of tumor antigens, organoid‐based evaluation, and fitness of Vδ1 T cells. It may accelerate development of effective CAR‐T drugs for heterogeneous solid tumors.
- 9 December 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (4) , 2281-2291
Controllable synthesis and biomedical applications of bismuth-based nanospheres: enhanced photothermal therapy and CT imaging efficiency
We report the controllable synthesis of monodisperse and uniform bismuth-based (Bi2S3, Bi, and Bi2O3) nanoparticles, and evaluate their potential for CT imaging and photothermal therapy applications.
- 9 December 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 17 (4) , 2281-2291
Controllable synthesis and biomedical applications of bismuth-based nanospheres: enhanced photothermal therapy and CT imaging efficiency
We report the controllable synthesis of monodisperse and uniform bismuth-based (Bi2S3, Bi, and Bi2O3) nanoparticles, and evaluate their potential for CT imaging and photothermal therapy applications.
- Open Access
- 1 July 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (7) , 3354-3369
Comprehensive analysis to identify the relationship between CALD1 and immune infiltration in glioma
Background: An accumulating number of studies show that CALD1 is associated with a variety of tumor microenvironments (TME) and is closely related to patients’ survival. However, to the best of our knowledge, few studies examined the role of CALD1 in the immune microenvironment of glioma. The aim of this study is to investigate the potential correlation between CALD1 and the pathogenesis and progression of glioma, aiming to identify a novel therapeutic target. Methods: We assessed the role of CALD1 in pan-cancer and investigated the correlation between CALD1 and TME of glioma by bioinformatic analysis and experimental verification. Results: We found that CALD1 expression in glioma was associated with a variety of infiltrating immune cells. CALD1 can promote the development of glioma by affecting M2 macrophage infiltration. Also, we found that CALD1 was closely associated with tumor mutation burden, microsatellite instability, copy number variation, methylation, and stem cell index. Our clinical correlation study demonstrated that CALD1 was associated with overall survival, progression-free interval, and disease-specific survival in a variety of tumors. We verified the significantly high expression of CALD1 in glioma using quantitative real-time polymerase chain reaction (PCR) and Western blotting. Meanwhile, we also conducted relevant cell experiments to prove that CALD1 can affect the proliferation and migration ability of glioma cells in vitro. Conclusions: Our results confirmed that CALD1 may be a prognostic marker for glioma and a potential target for immunotherapy in the future.
- 1 July 2024
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 13 (7) , 3354-3369
Open AccessComprehensive analysis to identify the relationship between CALD1 and immune infiltration in glioma
Background: An accumulating number of studies show that CALD1 is associated with a variety of tumor microenvironments (TME) and is closely related to patients’ survival. However, to the best of our knowledge, few studies examined the role of CALD1 in the immune microenvironment of glioma. The aim of this study is to investigate the potential correlation between CALD1 and the pathogenesis and progression of glioma, aiming to identify a novel therapeutic target. Methods: We assessed the role of CALD1 in pan-cancer and investigated the correlation between CALD1 and TME of glioma by bioinformatic analysis and experimental verification. Results: We found that CALD1 expression in glioma was associated with a variety of infiltrating immune cells. CALD1 can promote the development of glioma by affecting M2 macrophage infiltration. Also, we found that CALD1 was closely associated with tumor mutation burden, microsatellite instability, copy number variation, methylation, and stem cell index. Our clinical correlation study demonstrated that CALD1 was associated with overall survival, progression-free interval, and disease-specific survival in a variety of tumors. We verified the significantly high expression of CALD1 in glioma using quantitative real-time polymerase chain reaction (PCR) and Western blotting. Meanwhile, we also conducted relevant cell experiments to prove that CALD1 can affect the proliferation and migration ability of glioma cells in vitro. Conclusions: Our results confirmed that CALD1 may be a prognostic marker for glioma and a potential target for immunotherapy in the future.